arrow
A

Adriano Venditti

University of Rome Tor Vergata
H指数:56
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

FLT3-ITD微小克隆在AML中的预后影响:EHA AML专业化工作组研究

2026-11-010
PRE
Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

FLT3-ITD突变白血病干细胞的表征:功能与临床见解

2026-09-280
OAAI
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

非适应证急性髓系白血病患者接受维奈克拉联合去甲基化药物的疗效:GIMEMA AML2320试验结果

2026-09-050
PRE
Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial

使用外周血通过流式细胞术测量成人急性髓系白血病残留病灶:GIMEMA AML1310前瞻性试验的最终报告

2026-09-020
OAAI
An Italian cartography of VEXAS‐related thrombosis

意大利学者对VEXAS相关血栓形成的制图研究

2026-08-170
OAAI
Real-Life Study on Gilteritinib-Related Infections (GilteRInf): An Italian SEIFEM Study

Gilteritinib相关感染的Real-Life研究(GilteRInf):一项意大利SEIFEM研究

2026-07-280
OAAI
Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia

全反式维A酸和三氧化二砷治疗急性早幼粒细胞白血病后的正常预期寿命

Leukemia
IF13.4
2026-06-080
OAAI
APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications

NPM1突变AML中APL样亚群:一种与早期血管并发症相关的独特免疫表型

2026-04-160
OA
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial

性别、疾病特征与急性髓系白血病患者的结局关系:GIMEMA AML1310试验的性别分层分析

2026-01-010
PRE
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

2025年急性髓系白血病微小残留病更新:ELN-DAVID微小残留病工作组共识文件

Blood
IF23.1
2025-12-160
OAAI
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

流式细胞术基线可测残留病评估中定量下限作为低水平截断值的预后相关性研究

Leukemia
IF13.4
2025-12-100
OA
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Sustained Remission in Relapsed/Refractory Diffuse Large B Cell Lymphoma Following Glofitamab Discontinuation Due to JC Virus Reactivation: Balancing Efficacy and Infectious Risk

由于JCV病毒再激活停用Glofitamab后,复发/难治性弥漫大B细胞淋巴瘤的持续缓解:平衡疗效与感染风险

2025-11-060
PRE
The contribution of IL-10 and IL-6 as potential biomarkers for detecting central nervous system involvement in non-Hodgkin lymphomas

IL-10和IL-6作为检测非霍奇金淋巴瘤中枢神经系统受累的潜在生物标志物的贡献

2025-10-280
OAAI